← All trials
NCT05284448
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2022
- Primary completion
- Sep 30, 2022
- Completion date
- Oct 31, 2022
- First posted
- Mar 17, 2022
- Last posted
- Mar 17, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Al Azhar UniversityLead sponsor
- Ain Shams UniversityStudy director
- Al Azhar UniversityOverall official - principal investigator
- Al Azhar UniversityReponsible party - principal investigator
- Al Azhar UniversityStudy chair
- Al Azhar UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.